FDA Approves KV’s Drug Manufacturing Plan

Law360, New York (September 2, 2009, 6:40 PM EDT) -- The U.S. Food and Drug Administration has signed off on KV Pharmaceutical Co.’s work plan that aims to clear up problems with its drug manufacturing and distribution practices, according to a filing with the U.S. Securities and Exchange Commission.

KV said Wednesday the FDA has accepted its work plan several months after the St. Louis-based company agreed to a consent decree with the agency that enjoined KV, its subsidiaries Ethex Corp. and Ther-Rx Corp., and its principal officers from making and distributing adulterated and unapproved drugs....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.